Last reviewed · How we verify

Misoprostol + vasopressin — Competitive Intelligence Brief

Misoprostol + vasopressin (Misoprostol + vasopressin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: prostaglandin analog + vasopressor. Area: Gastroenterology.

marketed Combination therapy: prostaglandin analog + vasopressor Prostaglandin receptor (EP3/EP4) and vasopressin V1 receptor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Misoprostol + vasopressin (Misoprostol + vasopressin) — University Hospital of the West Indies. Misoprostol and vasopressin work synergistically to reduce gastric acid secretion and promote mucosal protection while enhancing vasoconstriction to control bleeding.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Misoprostol + vasopressin TARGET Misoprostol + vasopressin University Hospital of the West Indies marketed Combination therapy: prostaglandin analog + vasopressor Prostaglandin receptor (EP3/EP4) and vasopressin V1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: prostaglandin analog + vasopressor class)

  1. University Hospital of the West Indies · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Misoprostol + vasopressin — Competitive Intelligence Brief. https://druglandscape.com/ci/misoprostol-vasopressin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: